A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Recruiting

Phase 3

NGN-401A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Sponsor:

Neurogene Inc.

Code:

NCT05898620

Conditions

Rett Syndrome

Eligibility Criteria

Sex: Female

Age: 3+

Healthy Volunteers: Not accepted

Interventions

NGN-401

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-24. This information was provided to ClinicalTrials.gov by Neurogene Inc. on 2025-12-17.